Home » Public Policy

Regulatory Affairs

The Economic Contributions of the Biotechnology Industry

This report presents the estimates of the significant financial contributions of the biotechnology industry to the U.S. economy and to revenues collected by the federal, state and local governments.

Hindering Progress: Gene Patent Limits Could Impede Innovation

A new federal recommendation could hinder innovations from biotechnology R&D by limiting gene patents and licenses.

Bright Spot for Biotech: Golden State Leads in Jobs
Rare Diseases: Can We Speed Treatments?
BioBytes: Genetically Engineered Animals

Disease resistant animals, environmentally friendly livestock, pharmaceuticals produced by goats - are these really possible?

Regulatory Relief: House Passes SOX Relief Bill

In 2010, a lessening of the regulatory burden on biotech startups looks promising.

BioBytes: What are biosimilars?

Biosimilars, also known as follow-on biologics, may eventually expand access and provide patients a more affordable alternative to innovative, lifesaving medicines. 

Indirect Land Use Change, Low Carbon Fuel Standards, & Cap and Trade

Biofuels have the potential to play a critical role in addressing climate change

Tricia Brooks and James Trussell Discuss Stem Cell Research and Parkinson's Cures

BIO supports all avenues of research to investigate therapies for debilitating diseases such as Parkinson's.

The Importance of President Obama's Executive Order on Embryonic Stem Cells

In this interview, BIO President and CEO Jim Greenwood explains the promise of stem cell research and why it is an important first step in bringing new therapies to patients.

Regulatory Framework for GE Animals and their Products

BIO and its members engaged in animal biotechnology support a strong federal regulatory system to oversee development and approval of all genetically engineered (GE) animals and the products derived from them.

Guide to Biotechnology 2008

We have used the biological processes of microorganisms for 6,000 years to make useful food products, such as bread and cheese, and to preserve dairy products.

2007-2008 BIO Milestones

Today, the biotechnology industry is enjoying more success and influence than ever before. Our industry’s innovations continue to improve the lives of people worldwide, and the advancement of these innovations is supported by the work of BIO.

Milestones in 2006-2007

What happens in Washington influences biotechnology progress every bit as much as what happens on Wall Street or in the lab.

The Measure of a Great Industry is Who's Listening

In June 2003, the Biotechnology Industry Organization (BIO) brought its annual convention to Washington, D.C., setting the stage for an unprecedented exchange of views and expectations between biotechnology leaders and our nation’s top public officials.

Letters, Testimony & Comments

BIO Comments on the Indian DOP Report on Price Negotiation of Patented Drugs
June 19 2013
We understand the challenges that India faces with respect to healthcare and the innovative biotechnology industry stands ready to work with India to help address them.  
BIO Submits Comments on Brazil Rare Diseases Public Consultation
June 7 2013
BIO applauds the government of Brazil for taking steps towards developing regulatory requirements to ensure patients suffering from rare diseases have access to treatment.   
BIO's letter to FL Governor Scott Regarding Substitution of Biosimilar Medicines
May 8 2013
BIO  urges Florida Governor Scott to sign House Bill 365 – a bill related to the substitution of biologic and biosimilar medicines – which recently passed out of the Legislature.
PBRER: BIO Comments on Postmarket Periodic Safety Reports in the International Conference on Harmonisation E2C(R2) Format
May 8 2013
BIO thanks the Food and Drug Administration for the opportunity to submit comments on the “Draft Guidance for Industry on Providing Postmarket Periodic Safety Reports in the International Conference on Harmonisation E2C(R2) Format .”
Benefit-Risk: BIO Comments on FDA's Prescription Drug User Fee Act V Benefit-Risk Plan
May 7 2013
BIO thanks the Food and Drug Administration for the opportunity to submit comments on the FDA Draft Plan on “Structured Approach to Benefit-Risk Assessment in Drug Regulatory Decision Making.”
More Letters, Testimony & Comments →

Press Releases

Governor Kitzhaber Signs Legislation to Create Pathway for Substitution of Biologic Drugs
June 7 2013
Oregon Governor John Kitzhaber signed legislation on Thursday, June 6 designed to address the regulatory issues related to the interchangeability of biological medicines.
BIO to Use ViS Analytics to Streamline Pediatric Clinical Research
May 7 2013
Pediatric research is essential to study the effects of new therapeutics in children.
Biosimilars Bill Seeks To Notify Patients & Doctors of Changes to Prescriptions
April 3 2013
The Biotechnology Industry Organization (BIO) and BioFlorida commend the Florida Senate Committee on Health Policy for passage of Senate Bill 732 out of committee.
Governor McDonnell Signs First in Nation Biosimilars Bill; Patients To Be Notified If Doctor's Prescription Changed
March 21 2013
In statehouses around the country, lawmakers are beginning to address the complexities of cutting-edge biotech drugs and the regulatory issues related to the interchangeability of biosimilar medicines.
Ken Lisaius Named BIO's Vice President of Communications
January 23 2013
Ken Lisaius has been named Vice President of Communications at BIO.
More Press Releases →